IP Library Granted Patent US 11,058,714
Granted Patent B2
US 11,058,714 · App. 16/439,563 · Granted Jul 13, 2021

Administration of synergistic amounts of modified citrus pectin and honokiol to treat inflammation and anti-oxidant needs

Inventor: Isaac Eliaz (Santa Rosa, CA)
Assignee: ECONUGENICS, INC.
A61K31/732A61K9/0007A61K9/0056A61K31/05A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,058,714
App. No.
16/439,563
Granted
Jul 13, 2021
Kind
B2
Abstract

A method of inhibiting or reducing inflammation in a mammal comprises administering MCP or similar Gal-3 binding moiety with honokiol in a range of about 8-10:1, by weight, MCP to honokiol. By pursuing complimentary pathways, a synergistic combination is achieved, where the reduction or degree of inflammation inhibition is greater than would be expected by the added administration of these two agents. The inflammation may be manifested as gingivitis, which may be addressed by a preparation comprising honokiol and MCP, or an MCP equivalent, in the indicated range by weight, where they are in the form of an oral rinse, lozenge, sucking candy, toothpaste or tablet.

Claims (6)

1. A method of treating gingivitis in a mammalian patient, wherein said method comprises: identifying a mammalian patient that can benefit from a reduction or inhibition of gingivitis, administering to the oral cavity of said patient a combination of honokiol and MCP in amounts that synergistically reduce or inhibit inflammation in said oral cavity, wherein said combination of honokiol and MCP is in the form of an oral rinse, lozenge, tablet, sucking candy or toothpaste.

2. The method of claim 1 , wherein said administration of honokiol and

MCP to the oral cavity is effected at least twice daily to inhibit or reduce gingivitis.

3. The method of claim 1 , wherein said combination of honokiol and MCP is in the form of an oral rinse.

4. The method of claim 3 , wherein said oral rinse is effervescent.

5. The method of claim 1 , wherein said honokiol is administered in an amount, as oral equivalents, of 2-500 mg/kg of body weight/day and said MCP is administered, in oral equivalents, of 10-700 mg/kg/day.

Assignments (2)
ENTITY CONVERSION Recorded Dec 18, 2024
From: ECONUGENICS, INC.
To: ECONUGENICS, LLC
Reel/Frame 069736/0297 →
SECURITY INTEREST Recorded Apr 28, 2023
From: ECONUGENICS, LLC
To: ANTARES CAPITAL LP, AS COLLATERAL AGENT
Reel/Frame 063476/0445 →
Continuity (2)
Continuation In Part 15181726 · Jun 14, 2016
Related Publication 20190290679A1 · Sep 26, 2019